JNJ-61186372, Carboplatin 10 mg/ml Intravenous Infusion, CARBOPLATIN , Pemetrexed Seacross 500 mg powder for concentrate for solution for infusion, PEMETREXED
61186372NSC3001
Phase 3 small_molecule active
Quick answer
JNJ-61186372, Carboplatin 10 mg/ml Intravenous Infusion, CARBOPLATIN , Pemetrexed Seacross 500 mg powder for concentrate for solution for infusion, PEMETREXED for EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active